Article | August 16, 2022

Steps To Consider To Reduce Risk Of Biopharma Component Shortages

Source: Qosina Corporation

By Paul Priebe


The supply chain woes resulting from the COVID-19 pandemic have highlighted the risks of supply interruptions across all industries and products. Ensuring adequate supply chain of components used in medical devices and in vitro diagnostic devices or components used for the manufacture of drugs and biologics is more challenging and more critical than ever.

Overall, implementing a supply risk mitigation strategy and partnering with the right component vendor are key actions in improving your own supply chain resiliency and maintaining your market position. Find out what steps you can take to reduce the risk of component shortages in medical devices and for the manufacture of drugs and biologics, and their consequences.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online